Starfire Investment Advisers Inc. raised its holdings in Pfizer Inc. (NYSE:PFE) by 7.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 32,692 shares of the biopharmaceutical company’s stock after purchasing an additional 2,218 shares during the quarter. Starfire Investment Advisers Inc.’s holdings in Pfizer were worth $1,069,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of the business. New England Investment & Retirement Group Inc. purchased a new stake in shares of Pfizer in the 1st quarter valued at $26,000. Lion Street Advisors LLC purchased a new stake in shares of Pfizer in the 1st quarter valued at $27,000. Benjamin Edwards Inc. raised its holdings in shares of Pfizer by 49.8% in the 1st quarter. Benjamin Edwards Inc. now owns 1,008 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 335 shares during the period. Disciplined Investments LLC raised its holdings in shares of Pfizer by 43.3% in the 1st quarter. Disciplined Investments LLC now owns 1,148 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 347 shares during the period. Finally, Efficient Wealth Management LLC purchased a new stake in shares of Pfizer in the 1st quarter valued at $50,000. Institutional investors own 70.28% of the company’s stock.
Several equities research analysts recently issued reports on PFE shares. Barclays cut their price objective on Pfizer from $37.00 to $35.00 in a report on Monday, June 1st. Royal Bank of Canada reaffirmed a “buy” rating and issued a $44.00 price target on shares of Pfizer in a research report on Monday, April 27th. Piper Sandler boosted their price objective on Pfizer from $18.50 to $24.00 in a research report on Friday, June 26th. Morgan Stanley reduced their target price on shares of Pfizer from $43.00 to $36.00 and set an “equal weight” rating on the stock in a report on Thursday, April 2nd. Finally, JPMorgan Chase & Co. reduced their target price on shares of Pfizer from $37.00 to $36.00 and set a “neutral” rating on the stock in a report on Monday, June 1st. Ten investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Pfizer has a consensus rating of “Hold” and an average target price of $38.72.
PFE stock traded down $0.30 during midday trading on Thursday, reaching $33.45. 10,862,393 shares of the company were exchanged, compared to its average volume of 33,589,784. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.78 and a current ratio of 1.02. Pfizer Inc. has a 1-year low of $27.88 and a 1-year high of $44.10. The stock’s 50-day simple moving average is $35.02 and its 200 day simple moving average is $36.10. The company has a market cap of $187.48 billion, a price-to-earnings ratio of 12.10, a price-to-earnings-growth ratio of 2.66 and a beta of 0.68.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, April 28th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.09. Pfizer had a net margin of 31.17% and a return on equity of 25.76%. The company had revenue of $12.03 billion for the quarter, compared to analysts’ expectations of $11.38 billion. During the same quarter last year, the company earned $0.85 earnings per share. The firm’s revenue for the quarter was down 8.3% on a year-over-year basis. On average, research analysts anticipate that Pfizer Inc. will post 2.88 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 31st will be issued a dividend of $0.38 per share. The ex-dividend date is Thursday, July 30th. This represents a $1.52 dividend on an annualized basis and a yield of 4.54%. Pfizer’s payout ratio is currently 51.53%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Article: Cash Flow Analysis in Stock Selection
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.